Meet with...Novo Ventures

Nov 29 2017https://www.eventbrite.com/e/meet-withnovo-ventures-tickets-37042904324

Do you want to meet with one of the most active Life Science investors in the World? Novo Ventures is the venture investment vehicle for Novo Holdings A/S – a holding and investment company that manages ~$45B of assets on behalf of the Novo Nordisk Foundation.


Program Overview:
Novo Ventures is structured as an evergreen fund with an annual total of $350M to invest in private and public life science companies in North America and Europe. Their team identifies opportunities by leveraging a local presence in leading global biotech hubs and typically co-invests with other life sciences funds as either a lead or co-lead investor.

Novo Ventures has a strong focus on pre-commercial therapeutics and commercial med-tech companies, with opportunistic investments in diagnostics and research tools, and, more recently, digital health. Their team of professionals in Boston Copenhagen, London and San Francisco has an active portfolio of more than 50 companies and has invested in more than 140 companies since 2000.

For more information on Novo Ventures, visit http://www.novo.dk/ventures/about


Peter Moldt and Jennifer K. Lee from Novo Ventures will be in attendance to provide an overview presentation on Novo Ventures’ key areas of interest and venture investment philosophy. Novo Ventures will also be meeting 1-on-1 with select companies after the presentation.


Venue:
CIC Cambridge
Havana Room
1 Broadway
Cambridge, MA 02142
Map It


Event Partner:
Thank you to our in-kind sponsor, CIC.



Speakers:
Peter Moldt | Partner, Novo Ventures read bio»
Jennifer K. Lee | Associate, Novo Ventures read bio»


Agenda:
10:30AM | Registration and Networking
11:00 AM | Presentation and Q&A
11:45 AM | Networking Lunch
1:00-5:00 PM | One-on-One Meeting*

*Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due November 3. Apply Here.


Fees:

Presentation
$25 | General Public
$35 | Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on November 28 (or sold out).

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Companies must Apply for a one-on-one meeting ahead of time. The one-on-one application period will close on Friday November 3, 2017. Your application will be reviewed and you will be notified of acceptance by Wednesday November 15, 2017. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.


Speakers' Biographies:

Peter Moldt, Ph.D. | Partner, Novo Ventures
Peter joined Novo Ventures in San Francisco, California in 2012. He is Chairman of the Board of Directors of Allakos and a member of the Board of Directors of Corvus Pharmaceuticals, Bolt Therapeutics, E-Scape Bio, Spruce Biosciences and Tioma Therapeutics. Previously, he was a board member of Cytochroma, HemoFocus, Neurokey and Orphazyme.

In 2004, Peter co-founded Curalogic A/S, served as CEO until 2009 and took the company public in 2006. From 2000-2004, he was Chief Operating Officer of 7TM Pharma A/S, which he also co-founded. Previously, he worked for 11 years with NeuroSearch A/S, where he was responsible for all aspects of pre-clinical and clinical drug development.

Peter holds a PhD in medicinal chemistry from the Royal Danish School of Pharmacy. He has also been a post doc with Yale University's department of organic chemistry.


Jennifer K. Lee, Ph.D | Associate, Novo Ventures
Jeni joined Novo Ventures (US) Inc. in Boston, MA in 2016. Previously, Jeni supported the Director of Research at Aquilo Capital Management in San Francisco, CA, where she helped assess investment opportunities of small cap biotech companies. She also has experience in industry research, having interned in the Late Stage Product Research and Development group at Genentech. Jeni was a co-founder of ViVita Technologies, Inc., a cardiovascular-focused medtech startup with a platform to generate immune-compatible tissues from animal sources. Jeni earned her PhD in Biomedical Engineering with a Designated Emphasis in Biotechnology from the University of California, Davis, where she studied functional cartilage tissue engineering. She received her BS in Bioengineering from the University of California, Berkeley.



About the Meet With... Series:

The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.

Share